TargetMol

Nodinitib-1

Product Code:
 
TAR-T6591
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6591-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6591-1mL1 mL * 10 mM (in DMSO)£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6591-10mg10mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6591-25mg25mg£186.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6591-50mg50mg£251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6591-100mg100mg£371.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6591-200mg200mg£524.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Nodinitib-1 is a potent and selective NOD1 inhibitor with an IC50 of 0.56 μM.
CAS:
799264-47-4
Formula:
C14H13N3O2S
Molecular Weight:
287.34
Pathway:
Apoptosis; Immunology/Inflammation; NF-κb
Purity:
0.9998
SMILES:
Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12
Target:
TNF; NOD-like Receptor (NLR); NOD

References

Khan PM et al. ACS Med Chem Lett, 2011, 2(10), 780-785. Correa RG et al. Chem Biol, 2011, 18(7), 825-832. Zhang Y, Li N, Yuan G, et al. Upregulation of NOD1 and NOD2 contribute to cancer progression through the positive regulation of tumorigenicity and metastasis in human squamous cervical cancer. BMC medicine. 2022, 20(1): 1-15.